Related references
Note: Only part of the references are listed.Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets
Z. M. Younossi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
CIRCULATION (2014)
Interactions Between the Intestinal Microbiome and Liver Diseases
Bernd Schnabl et al.
GASTROENTEROLOGY (2014)
Free Cholesterol Accumulation in Hepatic Stellate Cells: Mechanism of Liver Fibrosis Aggravation in Nonalcoholic Steatohepatitis in Mice
Kengo Tomita et al.
HEPATOLOGY (2014)
Association Between the PNPLA3 (rs738409 C>G) Variant and Hepatocellular Carcinoma: Evidence From a Meta-Analysis of Individual Participant Data
Eric Trepo et al.
HEPATOLOGY (2014)
Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease
A. Yesil et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Potential of incretin-based therapies for non-alcoholic fatty liver disease
Susan L. Samson et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients
Salvatore Petta et al.
JOURNAL OF HEPATOLOGY (2013)
The role of angiotensin II in nonalcoholic steatohepatitis
E. Matthew Morris et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Dietary Omega-3 Fatty Acid Deficiency and High Fructose Intake in the Development of Metabolic Syndrome, Brain Metabolic Abnormalities, and Non-Alcoholic Fatty Liver Disease
Artemis P. Simopoulos
NUTRIENTS (2013)
Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial
Carly Eckard et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
Caffeine is protective in patients with non-alcoholic fatty liver disease
A. Birerdinc et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
E. Boettcher et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease
S. Petta et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome
Yusuf Yilmaz et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)
Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: A narrative review
Ruben Hernaez
GASTROENTEROLOGIA Y HEPATOLOGIA (2012)
A High-Cholesterol Diet Exacerbates Liver Fibrosis in Mice via Accumulation of Free Cholesterol in Hepatic Stellate Cells
Toshiaki Teratani et al.
GASTROENTEROLOGY (2012)
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Naga Chalasani et al.
GASTROENTEROLOGY (2012)
Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis
Jeffrey W. Molloy et al.
HEPATOLOGY (2012)
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism
Claudia O. Zein et al.
HEPATOLOGY (2012)
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Helen M. Parker et al.
JOURNAL OF HEPATOLOGY (2012)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review
Christian Thoma et al.
JOURNAL OF HEPATOLOGY (2012)
Genetic variants in candidate genes influencing NAFLD progression
Michelino Di Rosa et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
G. Vernon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort
Barham K. Abu Dayyeh et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Relationship Between the Pattern of Hepatic Iron Deposition and Histological Severity in Nonalcoholic Fatty Liver Disease
James E. Nelson et al.
HEPATOLOGY (2011)
Pentoxifylline Improves Nonalcoholic Steatohepatitis: A Randomized Placebo-Controlled Trial
Claudia O. Zein et al.
HEPATOLOGY (2011)
Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents The TONIC Randomized Controlled Trial
Joel E. Lavine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Eric A. Klein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
DRUG THERAPY n-3 Fatty Acids in Cardiovascular Disease
Raffaele De Caterina
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Chrysi Koliaki et al.
Diabetes Therapy (2011)
Weight reduction for non-alcoholic fatty liver disease
Lijun Peng et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
G. S. Masterton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis
M. O. Rakoski et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
The Effect of Lifestyle Changes in Non-Alcoholic Fatty Liver Disease
Elena Centis et al.
DIGESTIVE DISEASES (2010)
The Role of Cytokines in Non-Alcoholic Fatty Liver Disease
Herbert Tilg
DIGESTIVE DISEASES (2010)
High-Dose Ursodeoxycholic Acid Therapy for Nonalcoholic Steatohepatitis: A Double-Blind, Randomized, Placebo-Controlled Trial
Ulrich F. H. Leuschner et al.
HEPATOLOGY (2010)
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
Herbert Tilg et al.
HEPATOLOGY (2010)
Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes
Dori Bilik et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation
Evangelos Cholongitas et al.
LIVER INTERNATIONAL (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Giovanni Targher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
R. Loomba et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Noreen Hossain et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Thiazolidinediones and the liver in humans
Hannele Yki-Jarvinen
CURRENT OPINION IN LIPIDOLOGY (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Crosstalk between insulin and angiotensin II signalling systems
F. Folli et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2009)
Orlistat for Overweight Subjects with Nonalcoholic Steatohepatitis: A Randomized, Prospective Trial
Stephen A. Harrison et al.
HEPATOLOGY (2009)
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C
Kathleen E. Corey et al.
LIVER INTERNATIONAL (2009)
Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
John Willy Haukeland et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Fructose consumption as a risk factor for non-alcoholic fatty liver disease
Xiaosen Ouyang et al.
JOURNAL OF HEPATOLOGY (2008)
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia
Hideyuki Hyogo et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Weight-loss outcomes: A systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up
Marion J. Franz et al.
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION (2007)
The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease
Filiz Akyuez et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman et al.
HEPATOLOGY (2007)
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects
Amalia Gastaldelli et al.
GASTROENTEROLOGY (2007)
Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis
Gulden Baskol et al.
CLINICAL BIOCHEMISTRY (2007)
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention - Systematic review and meta-analysis
Goran Bjelakovic et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Review:: Peroxisome proliferator-activated receptor γ and adipose tissue -: Understanding obesity-related changes in regulation of lipid and glucose metabolism
Arya M. Sharma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells
Yongzhong Wei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
Shira Zelber-Sagi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study
M Capanni et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
KD Lindor et al.
HEPATOLOGY (2004)
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
G Marchesini et al.
HEPATOLOGY (2003)
Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
AJ Sanyal et al.
GASTROENTEROLOGY (2001)
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
A Poonawala et al.
HEPATOLOGY (2000)
Share Paper
